Grazoprevir potassium salt - 10mM in DMSO, high purity , CAS No.1206524-86-8(DMSO)

Item Number

G655458

• Specifications & Purity: 10mM in DMSO
• Storage Temp: Desiccated,Store at -80°C
• Shipped In: Ice chest + Ice pads

Product Description

Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K i s of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively Grazoprevir potassium salt inhibits SARS-CoV-2 3CL pro activity

In Vitro

In biochemical assays, Grazoprevir (MK-5172) is effective against a panel of major genotypes and variants engineered with common resistant mutations, with K i of 0.01±<0.01 nM (gt1b), 0.01±0.01 nM (gt1a), 0.08±0.02 nM (gt2a), 0.15±0.06 nM (gt2b), 0.90±0.2 nM (gt3a), 0.07±0.01 nM (gt1b R155K ), 0.14±0.03 nM (gt1b D168V ), 0.30±0.04 nM (gt1b D168Y ), 5.3±0.9 nM (gt1b A156T ), and 12±2 nM (gt1b A156V ), respectively. In the replicon assay, Grazoprevir demonstrates subnanomolar to low-nanomolar EC 50 s against genotypes 1a, 1b, and 2a, with EC 50 s of 0.5±0.1 nM, 2±1 nM, and 2±1 nM for gt1b con1 , gt1a, and gt2a, respectively. Grazoprevir is potent against a panel of HCV replication mutants NS5A (Y93H) (EC 50 =0.7±0.3 nM), NS5B nucleosides (S282T) (EC 50 =0.3±0.1 nM), and NS5B (C316Y) (EC 50 =0.4±0.2). Grazoprevir (MK-5172) maintains the excellent potency against the gt 3a enzyme as well as a broad panel of mutant enzymes, has excellent potency in the replicon system [gt1b IC 50 (50% NHS)=7.4 nM; gt1a IC 50 (40% NHS)=7 nM], and shows excellent rat liver exposure. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Grazoprevir (MK-5172) demonstrates efficacy in vivo against chronic-HCV-infected chimpanzees . When dosed to dogs, Grazoprevir (MK-5172) shows low clearance of 5 mL/min/kg and a 3 h half-life after iv dosing and has good plasma exposure (AUC=0.4 μM h) after a 1 mg/kg oral dose. Dog liver biopsy studies showed that the liver concentration of Grazoprevir after the 1 mg/kg oral dose is 1.4 μM at the 24 h time point. Similar to its behavior in rats, Grazoprevir demonstrates effective partitioning into liver tissue and maintains high liver concentration, relative to potency, 24 h after oral dosing in dogs. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IC50& Target:Ki: 0.01±<0.01 nM (gt1b), 0.01±0.01 nM (gt1a), 0.08±0.02 nM (gt2a), 0.15±0.06 nM (gt2b), 0.90±0.2 nM (gt3a)